Lapam Capital
(龙磐投资)

Lapam Capital, headquartered in Beijing, is a leading biopharmaceutical venture capital firm in China. It currently manages five RMB-denominated funds and one USD-denominated fund, with total assets under management (AUM) exceeding RMB 10 billion. It is the only biopharmaceutical investment institution in China that has received capital support from both the National Social Security Fund (NSSF) and the National Small and Medium Enterprises Development Fund (SME Fund).  

Riverhead Capital
(阳光融汇)

Founded in 2015, Riverhead Capital is a private equity firm based in Beijing, China. The firm focuses on venture and growth opportunities. It invests in a diversified range of industries, including business services, consumer discretionary, energy, financial services, healthcare, industrials, information technology, raw materials, real estate, and TMT in China.

Frees Fund
(峰瑞资本)

FreeS Fund is a venture capital firm founded in 2015 and headquartered in Shanghai, China. The firm operates both RMB and USD fund vehicles, managing assets reported at approximately 3.6 billion RMB across multiple specialized funds. FreeS Fund has established itself as a legitimate institutional player in the Chinese venture capital landscape, focusing on early-stage and early growth-stage startups.

Gree Investment
(格力产投)

Founded in 2017, Gree Ventures is a corporates venture capital firm of Zhuhai Gree based in Zhuhai, China. It focuses on making investments in sectors like integrate circuit, advanced manufacturing, healthcare, and information technology.

Hanne Capital
(翰颐资本)

Hanne Capital is a healthcare-focused venture capital and private equity fund based in Greater China, investing in early-stage and growth-stage opportunities within the healthcare and biotechnology sectors. The firm specializes in novel drugs, medical devices, and innovative therapeutic platforms, such as peripheral and neurovascular interventional devices, immunotherapy, and antibody drug development. Operating with a typical "7+2" fund cycle, its portfolio features Zylox-Tonbridge Medical (HK:02190), which went public approximately three years post-investment, and HiFiBiO Therapeutics, which secured a $67 million Series C round in 2019. Hanne Capital has also co-invested alongside notable firms such as IDG Capital, Sequoia Capital China, and VI Ventures. Founded in 2017 by Edward Zhou, the firm targets companies with strong founding teams and intrinsic business value.

GF Qianhe Capital
(广发乾和）

Founded in 2012, GF Qianhe is a venture capital firm based in Beijing, China. The firm seeks to make investments in sectors such as advanced manufacturing, technology, semiconductors, and healthcare.